Bachem Holding AG
BANB
Classement en actions
#2516
Bachem Holding AG serves pharmaceutical and biotechnology companies globally,... Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Prix de l'action
$100.60
Capitalisation boursière
$7.54B
Changement (1 jour)
-1.49%
Changement (1 an)
49.53%
Pays
CH
Échange Bachem Holding AG (BANB)
Catégorie
Healthcare
Bénéfices pour Bachem Holding AG (BANB)
Bénéfices en 2026 TTM : 0
Selon les derniers rapports financiers de Bachem Holding AG, les bénéfices actuels de l'entreprise sont de 0. En 2026, l'entreprise a réalisé un bénéfice de 0, égal à celui de 2026 qui était de 0. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour Bachem Holding AG de 2002 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2025 | $197.08M | 31.67% |
| 2024 | $149.68M | 1.35% |
| 2023 | $147.69M | 21.84% |
| 2022 | $121.22M | -15.88% |
| 2021 | $144.11M | 42.32% |
| 2020 | $101.26M | 62.26% |
| 2019 | $62.40M | 12.36% |
| 2018 | $55.54M | 11.92% |
| 2017 | $49.63M | 10.07% |
| 2016 | $45.08M | 20.90% |
| 2015 | $37.29M | 1.92% |
| 2014 | $36.59M | 12.98% |
| 2013 | $32.38M | 52.96% |
| 2012 | $21.17M | 62.51% |
| 2011 | $13.03M | -61.93% |
| 2010 | $34.22M | -23.54% |
| 2009 | $44.76M | -29.32% |
| 2008 | $63.33M | -12.95% |
| 2007 | $72.75M | 49.11% |
| 2006 | $48.79M | 30.20% |
| 2005 | $37.47M | 1.17% |
| 2004 | $37.04M | -5.60% |
| 2003 | $39.24M | 21.47% |
| 2002 | $32.30M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| $1.95B | - |
NL
|
|
| - | - |
CH
|
